Mutation detection and accurate diagnosis of extensively drug-resistant tuberculosis: Report from a tertiary care center in India

Journal of Clinical Microbiology

Volumn 49, Issue 4, 2011, Pages 1588-1590

  Ajbani, Kanchan ^a   Rodrigues, Camilla ^b   Shenai, Shubhada ^a   Mehta, Ajita ^b  

^a Department of Research ^*  (India)

^b P D HINDUJA NATIONAL HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; AMIKACIN; ASPARTIC ACID; CAPREOMYCIN; GLYCINE; ISONIAZID; KANAMYCIN; LYSINE; MOXIFLOXACIN; OFLOXACIN; RIFAMPICIN; SERINE; THREONINE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENE TARGETING; GENETIC SCREENING; GYRA GENE; GYRB GENE; HUMAN; INDIA; INHA GENE; KATG GENE; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RPOB GENE; RRS GENE; TERTIARY HEALTH CARE;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; BACTERIAL TYPING TECHNIQUES; CLUSTER ANALYSIS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; GENOTYPE; HUMANS; INDIA; MOLECULAR TYPING; MUTATION, MISSENSE; MYCOBACTERIUM TUBERCULOSIS;

MYCOBACTERIUM TUBERCULOSIS;

EID: 79953888414     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00113-11     Document Type: Article

References (29)

1. Alangaden, G., E. Manavathu, S. Vakulenko, N. Zvonok, and S. Lerner. 1995. Characterization of fluoroquinolone resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients. Antimicrob. Agents Chemother. 39:1700-1703.
2. Alangaden, G., et al. 1998. Mechanism of resistance to amikacin and kanamycin in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 42: 1295-1297. (Pubitemid 28227943)
3. Almeida, D., et al. 2005. High incidence of the Beijing genotype among multidrugresistant isolates of Mycobacterium tuberculosis in a tertiary care center in Mumbai, India. Clin. Infect. Dis. 40:881-886. (Pubitemid 40365511)
4. Arora, J., et al. 2009. Characterization of predominant Mycobacterium tuberculosis strains from different subpopulations of India. Infect. Genet. Evol. 9:832-839.
5. Aubry, A., et al. 2006. Novel gyrase mutation in quinolone resistant and hypersusceptible clinical isolates of Mycobacterium tuberculosis: Functional analysis of mutant enzymes. Antimicrob. Agents. Chemother. 50:104-112. (Pubitemid 43042909)
6. Boer, M., A. Zanden, and D. Soolingen. 2004. Simultaneous detection and typing of Mycobacterium tuberculosis complex bacteria. Clin. Lab. Int. http://www.cli -online.com/fileadmin/pdf/datasheet/simultaneous-detection-and- typing-of -mycobacterium-tuberculosis-complex-bacteria.pdf.
7. Brudey, K., et al. 2006. Mycobacterium tuberculosis complex genetic diversity: Mining the fourth international spoligotyping database (SpolDB4) for classification, population genetics and epidemiology. BMC Microbiol. 1471: 6-23.
8. Cheng, A., et al. 2004. Multiplex PCR amplimer conformation analysis of rapid detection of gyrA mutations in fluroquinolone resistant Mycobacterium tuberculosis clinical isolates. Antimicrob. Agents Chemother. 48:596-601. (Pubitemid 38141721)
9. Eldholm, V., et al. 2006. A first insight into the genetic diversity of Mycobacterium tuberculosis in Dar es Salaam, Tanzania, assessed by spoligotyping. BMC Microbiol. 76(6):1-7.
10. Elsevier. 2006. XDR-TB-TB-a global threat. Lancet 368:964.
11. Gandhi, N. R., et al. 2006. Extensively drug resistant tuberculosis as a cause of death in patients' co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368:1575-1580. (Pubitemid 44780738)
12. Gupta, A., M. Espinal, and M. Raviglione. 2001. Should tuberculosis programmes invest in second-line treatments for multi drug resistant tuberculosis (MDR-TB). Int. J. Tuberc. Lung Dis. 12:1078-1079. (Pubitemid 34033207)
13. Kam, K. M., et al. 2006. Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug resistant Mycobacterium tuberculosis: Correlation with ofloxacin susceptibility. Microb. Drug Resist. 12:7-11.
14. Kocagoz, T., et al. 1996. Gyrase mutations in laboratory selected fluoroquinolone resistant mutants of mycobacterium tuberculosis H37Ra. Antimicrob. Agents Chemother. 40:1768-1774. (Pubitemid 26277791)
15. LoBue, P. 2009. Extensively drug-resistant tuberculosis. Curr. Opin. Infect. Dis. 22:167-173.
16. Maus, C., B. Plikaytis, and T. Shinnick. 2005. Molecular analysis of cross resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 49:3192-3197. (Pubitemid 41060560)
17. Maus, C., B. Plikaytis, and T. Shinnick. 2005. Mutation of tlyA confers capreomycin resistance in mycobacterium tuberculosis. Antimicrob. Agents Chemother. 49:571-577. (Pubitemid 40175664)
18. Perdigao, J., et al. 2010. Genetic analysis of extensively drug-resistant Mycobacterium tuberculosis strains in Lisbon, Portugal. J. Antimicrob. Chemother.65:224-227.
19. Rodrigues, C., et al. 2008. Drug susceptibility testing of Mycobacterium tuberculosis against second line drugs using the Bactec MGIT 960 System. Int. J. Tuberc. Lung Dis. 12:1449-1455.
20. Shah, S., et al. 2007. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg. Infect. Dis. 13:380-387.
21. Shenai, S, C. Rodrigues, and A. Mehta. 2009. Rapid speciation of 15 clinically relevant mycobacteria with simultaneous detection of resistance to rifampicin, isoniazid and streptomycin in Mycobacterium tuberculosis complex. Int. J. Infect. Dis. 13:46-58.
22. Shi, R., J. Zhang, C. Li, Y. Kazumi, and I. Sugawara. 2006. Emergence of ofloxacin resistance in Mycobacterium tuberculosis clinical isolates from China as determined by gyrA mutation analysis using denaturing high-pressure liquid chromatography and DNA sequencing. J. Clin. Microbiol. 44: 4566-4568. (Pubitemid 44937098)
23. Somerville, W., L. Thibert, K. Schwartzman, and M. Behr. 2005. Extraction of Mycobacterium tuberculosis DNA: A question of containment. J. Clin. Microbiol. 43:2996-2997. (Pubitemid 40827998)
24. Somoskovi, A., L. Parsons, and M. Salfinger. 2001. The molecular basis of resistance to isoniazid, rifampicin, and pyrazinamide in Mycobacterium tuberculosis. Respir. Res. 2:164-168. (Pubitemid 34187923)
25. Sun, Z., et al. 2008. Characterization of extensively drug resistant Mycobacterium tuberculosis clinical isolates in China. J. Clin. Microbiol. 46:4075-4077.
26. Suzuki, Y., et al. 1998. Detection of kanamycin resistant Mycobacterium tuberculosis by identifying mutations in the 16S rRNA gene. J. Clin. Microbiol.36:1220-1225. (Pubitemid 28208002)
27. Takiff, H., et al. 1994. Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob. Agents Chemother. 38:773-780. (Pubitemid 24114017)
28. Tsukamura, M., and S. Mizuno. 1975. Cross resistant relationships among the aminoglycoside antibiotics in Mycobacterium tuberculosis. J. Gen. Microbiol.88:269-274.
29. van Soolingen, D., P. W. Hermans, P. E. Dehaas, D. R. Soll, and J. D. van Embden. 1991. Occurrence and stability of insertion sequences in Mycobacterium tuberculosis complex strains: Evaluation of an insertion sequencedependent DNA polymorphism as a tool in the epidemiology of tuberculosis. J. Clin. Microbiol. 29:2578-2586.